Tiziana Life Sciences

Update in progress

TLSA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Tiziana Life Sciences Ltd is a biotechnology company focused on developing transformative therapies for neurodegenerative and lung diseases, primarily in the United States. Its lead immunology candidate is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody being explored for autoimmune conditions such as Crohn’s disease, ulcerative colitis, multiple sclerosis, type 1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. TZLS-501 is a fully human anti-IL-6 receptor monoclonal antibody for inflammatory and oncologic indications. Incorporated in 1998, it is headquartered in London.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive